Medium Chain Fatty Acids (MCFAs) for Enhanced Bacterial Infection Treatment

Brief Description

MCFAs provide a synergistic bactericidal effect in combination with antibiotics and bacteriophages to effectively treat antibiotic-resistant bacterial infections.

Full Description

Medium chain fatty acids (MCFAs) exhibit potent bactericidal activity against a broad range of gram-positive and gram-negative bacteria even at neutral pH. When used alongside antibiotics and bacteriophages, MCFAs enhance their efficacy by overcoming bacterial resistance, thus offering a superior treatment approach for infections caused by difficult pathogens like Stenotrophomonas maltophilia. This combinational therapy addresses limitations of current solutions such as slow antibiotic development and the narrow specificity of phage therapy.

Suggested uses

• Pharmaceutical formulations combining MCFAs with antibiotics or phages 
• Treatments for infections caused by multi-drug resistant bacteria 
• Cystic fibrosis patient infection management 
• Hospital-acquired infection therapies 
• Development of novel antimicrobial combination therapies 
• Adjunct therapy in clinical settings to enhance existing antibiotic regimens

Advantages

• Broad-spectrum bactericidal action effective at neutral pH 
• Synergistic enhancement of bacteriophage and antibiotic activity 
• Effective against antibiotic-resistant and opportunistic pathogens 
• Improved treatment potency against difficult bacteria like Stenotrophomonas maltophilia 
• Potential to reduce treatment resistance development 
• Versatile application with multiple antibiotic classes

Patent Status

Patent Pending